top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha DaRT Advanced Pancreatic Cancer Trial : Highly Promising Interim Results
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no...
Nov 28, 2023
ATM submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT for Recurrent Head & Neck Cancer
Jerusalem, November 20, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative...
Nov 20, 2023
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside...
Nov 19, 2023
Alpha Tau to Participate in November Investor Conferences
JERUSALEM, November 1, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Nov 1, 2023
ATM Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
JERUSALEM, October 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 30, 2023
Former U.S. Commissioner of FDA Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
JERUSALEM, October 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Oct 24, 2023
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Hadassah Medical Center
JERUSALEM, Sept. 14, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Sep 14, 2023
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
Aug 29, 2023
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 24, 2023
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...
Aug 21, 2023
bottom of page